Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Replimune Group, Inc. (REPL)

2.8500 +0.5800 (+25.55%)
At close: 4:00:00 PM EDT
2.8500 0.0000 (0.00%)
After hours: 6:12:55 PM EDT
Trade REPL on Coinbase
Chart Range Bar
Loading chart for REPL
  • Previous Close 2.2700
  • Open 2.3500
  • Bid 2.8300 x 900
  • Ask 2.9000 x 900
  • Day's Range 2.3200 - 2.9600
  • 52 Week Range 1.5000 - 13.2400
  • Volume 19,248,092
  • Avg. Volume 3,981,580
  • Market Cap (intraday) 235.332M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -3.4400
  • Earnings Date (est.) May 21, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.50

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

www.replimune.com

479

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: REPL

Trailing total returns as of 4/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

REPL
70.68%
S&P 500 (^GSPC)
3.84%

1-Year Return

REPL
67.72%
S&P 500 (^GSPC)
32.23%

3-Year Return

REPL
83.48%
S&P 500 (^GSPC)
71.97%

5-Year Return

REPL
90.96%
S&P 500 (^GSPC)
70.05%

Earnings Trends: REPL

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -70.93M

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-80M
-60M
-40M
-20M
0

Analyst Insights: REPL

View More

Analyst Price Targets

1.00 Low
3.50 Average
2.8500 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/13/2026
Analyst Cantor Fitzgerald
Rating Action Downgrade
Rating Neutral
Price Action --
Price Target --

Statistics: REPL

View More

Valuation Measures

Annual
As of 4/22/2026
  • Market Cap

    187.03M

  • Enterprise Value

    -5.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.89

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -43.24%

  • Return on Equity (ttm)

    -90.88%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -314.85M

  • Diluted EPS (ttm)

    -3.4400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    269.14M

  • Total Debt/Equity (mrq)

    36.26%

  • Levered Free Cash Flow (ttm)

    -172.75M

Compare To: REPL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: REPL

Fair Value

2.8500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: